The implementation of a diagnostic chain, including the Stockholm3 test, is already established in Stavanger, Norway, with 97% of family medicine clinics using it and sending samples to neighboring Sweden for analysis.26 While other blood- and urine-based biomarkers also offer higher sensitivity and specificity than PSA for detecting clinically significant prostate cancer, none has been compared with image-based screening. The gene discussed is KLK3; the disease is prostate carcinoma.